Such treatment affected NAA and glucose levels, which besides the energy-dependent NAA deficiency suggested by the authors could also be explained by the inhibition impact of Mn2+ against NAT8L (Figure 4E,F) [48]. The gene discussed is ASPNAT; the disease is N-acetylaspartate deficiency.